India markets closed
  • BSE SENSEX

    49,206.47
    +256.71 (+0.52%)
     
  • Nifty 50

    14,823.15
    +98.35 (+0.67%)
     
  • USD/INR

    73.3000
    -0.2900 (-0.39%)
     
  • Dow

    34,777.76
    +229.23 (+0.66%)
     
  • Nasdaq

    13,752.24
    +119.39 (+0.88%)
     
  • BTC-INR

    4,297,605.50
    +107,294.75 (+2.56%)
     
  • CMC Crypto 200

    1,480.07
    +44.28 (+3.08%)
     
  • Hang Seng

    28,610.65
    -26.81 (-0.09%)
     
  • Nikkei

    29,357.82
    +26.45 (+0.09%)
     
  • EUR/INR

    89.1880
    +0.3797 (+0.43%)
     
  • GBP/INR

    102.5309
    +0.2936 (+0.29%)
     
  • AED/INR

    19.9120
    -0.0790 (-0.40%)
     
  • INR/JPY

    1.4786
    -0.0008 (-0.05%)
     
  • SGD/INR

    55.3350
    +0.1290 (+0.23%)
     

Dr Reddy’s gains post announcing launch of Albendazole tablets in US market

abhinav lahoti
·1-min read

A leading multinational pharmaceutical company based in India & overseas, Dr Reddy’s Laboratories Limited (DRL), along with its subsidiaries, announced the launch of Albendazole tablets, USP in the US markets.  

Albendazole tablets, USP is a therapeutic equivalent generic version of Albenza tablets, 200 mg, which has been approved by United States Food & Drug Administration (USFDA). These tablets will be available in the market in 200 mg tablets in a bottle count size of two.   

Albendazole is an anthelmintic drug indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. It is also used for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.  

As per IQVIA Health, Albenza brand and generic has a market size of approximately US $27 million.  

At 10.16 am on Friday, the stock of Dr Reddy’s was trading at Rs 5,157.55, up by 1.10 per cent on BSE. 

---